8-KLeadership ChangesRegulation FDExhibits & Filings

BIOGEN INC. 8-K Report, Executive Changes (May 30, 2008)

Filed May 30, 2008For Securities:BIIB

Summary

Biogen Idec Inc. announced the appointment of Hans Peter Hasler as Chief Operating Officer (COO) effective May 29, 2008. This is a significant executive transition, with Mr. Hasler stepping into a key leadership role within the company. His compensation package for this new position includes approximately $270,000 in stock options and $270,000 in restricted stock units, to be awarded under the company's 2005 Omnibus Equity Plan. Mr. Hasler has a considerable history with Biogen, having held various senior international and commercial roles since joining in August 2001. His extensive experience in global neurology and international business operations positions him to contribute to Biogen's strategic objectives as COO. Investors should note that the exact number of shares for these awards will be determined by the stock's closing price on June 2, 2008.

Key Highlights

  • 1Hans Peter Hasler appointed Chief Operating Officer (COO) of Biogen Idec Inc.
  • 2Mr. Hasler's appointment is effective May 29, 2008.
  • 3Compensation includes approximately $270,000 in stock options.
  • 4Compensation also includes approximately $270,000 in restricted stock units.
  • 5Awards are subject to the Biogen Idec Inc. 2005 Omnibus Equity Plan.
  • 6Number of shares for awards will be based on the June 2, 2008 closing stock price.
  • 7Mr. Hasler has a long tenure with Biogen, holding various senior leadership positions.

Frequently Asked Questions

The appointment of Hans Peter Hasler as Chief Operating Officer is a significant executive leadership change. As COO, he will play a crucial role in overseeing the company's operations and executing its strategic goals. His extensive experience within Biogen, particularly in international markets and commercial operations, suggests a focus on leveraging existing strengths and driving operational efficiency.

Mr. Hasler will receive equity awards totaling approximately $540,000. This includes roughly $270,000 in stock options and $270,000 in restricted stock units. These awards are intended to align his interests with those of shareholders and incentivize long-term performance.

The exact number of shares subject to both the stock option and restricted stock unit awards will be determined by the closing price of Biogen Idec common stock on June 2, 2008. This date is significant as it's the first trading day of the month following his appointment.

No, this 8-K filing primarily concerns the appointment of a new Chief Operating Officer and the associated compensation. It does not contain detailed financial statements, business updates, or a forward-looking outlook. The information provided is related to executive management and compensation arrangements.